"{\n \"business_address\": \"ONE EDWARDS WAY, IRVINE, CA 92614\", \n \"business_phone_no\": \"9492502500\", \n \"ceo\": \"Michael A. Mussallem\", \n \"cik\": \"0001099800\", \n \"company_url\": \"www.edwards.com\", \n \"employees\": 11100, \n \"entity_legal_form\": \"CORPORATION\", \n \"entity_status\": \"ACTIVE\", \n \"hq_address1\": \"C/O The Corporation Trust Company\", \n \"hq_address2\": \"Corporation Trust Center\", \n \"hq_address_city\": \"Wilmington\", \n \"hq_address_postal_code\": \"19801\", \n \"hq_country\": \"United States of America\", \n \"hq_state\": \"California\", \n \"inc_country\": \"United States of America\", \n \"inc_state\": \"Delaware\", \n \"industry_category\": \"Health Services\", \n \"industry_group\": \"Medical Appliances & Equipment\", \n \"latest_filing_date\": \"2017-07-28\", \n \"legal_name\": \"Edwards Lifesciences Corp\", \n \"lei\": \"YA13X31F3V31L8TMPR58\", \n \"long_description\": \"Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients worldwide. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and their delivery systems for the nonsurgical replacement of heart valves. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral replacement, and minimally invasive aortic heart valve system; and tissue heart valves and repair products, which are used to replace or repair a patient's diseased or defective heart valve. In addition, it produces pericardial valves from biologically inert animal tissue; and provides heart valve repair therapies, including annuloplasty rings and systems. Further, the company offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function in surgical and intensive care settings; pulmonary artery catheters; and Oximetry Central Venous Catheters for continuous measurement of central venous oxygen saturation. Additionally, its critical care products include disposable pressure monitoring devices and closed blood sampling systems to protect patients and clinicians from infection; and peripheral vascular products used to treat endolumenal occlusive disease, such as embolectomy catheters for removing blood clots from peripheral blood vessels. The company distributes its products through direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1999 and is headquartered in Irvine, California.\", \n \"mailing_address\": \"ONE EDWARDS WAY, IRVINE, CA 92614\", \n \"name\": \"Edwards Lifesciences Corp\", \n \"sector\": \"Healthcare\", \n \"securities\": [\n  {\n   \"composite_figi\": \"BBG000BRXP69\", \n   \"composite_figi_ticker\": \"EW:US\", \n   \"currency\": \"USD\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XNYS\", \n   \"figi\": \"BBG000BRXP69\", \n   \"figi_exch_cntry\": \"US\", \n   \"figi_ticker\": \"EW:US\", \n   \"figi_uniqueid\": \"EQ0141500000001000\", \n   \"last_crsp_adj_date\": \"2015-12-14\", \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XNYS\", \n   \"primary_listing\": true, \n   \"security_name\": \"EDWARDS LIFESCIENCES CORP\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001SF2288\", \n   \"stock_exchange\": \"NYSE\", \n   \"ticker\": \"EW\"\n  }, \n  {\n   \"composite_figi\": \"BBG000BT0397\", \n   \"composite_figi_ticker\": \"EWL:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XBER\", \n   \"figi\": \"BBG000BT05L8\", \n   \"figi_exch_cntry\": \"GB\", \n   \"figi_ticker\": \"EWL:GB\", \n   \"figi_uniqueid\": \"EQ0141500000001001\", \n   \"last_crsp_adj_date\": \"2007-01-02\", \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XBER\", \n   \"primary_listing\": false, \n   \"security_name\": \"EDWARDS LIFESCIENCES CORP\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001SF2288\", \n   \"stock_exchange\": \"BER\", \n   \"ticker\": \"EWL\"\n  }, \n  {\n   \"composite_figi\": \"BBG000BT0397\", \n   \"composite_figi_ticker\": \"EWL:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XFRA\", \n   \"figi\": \"BBG000BT03P9\", \n   \"figi_exch_cntry\": \"GF\", \n   \"figi_ticker\": \"EWL:GF\", \n   \"figi_uniqueid\": \"EQ0141500000001001\", \n   \"last_crsp_adj_date\": \"2015-12-14\", \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XFRA\", \n   \"primary_listing\": false, \n   \"security_name\": \"EDWARDS LIFESCIENCES CORP\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001SF2288\", \n   \"stock_exchange\": \"FRA\", \n   \"ticker\": \"EWL\"\n  }, \n  {\n   \"composite_figi\": \"BBG00C5Z55X7\", \n   \"composite_figi_ticker\": \"EWCHF:XL\", \n   \"currency\": \"CHF\", \n   \"delisted_security\": true, \n   \"etf\": false, \n   \"exch_symbol\": \"^XLON\", \n   \"figi\": \"BBG00C5Z5665\", \n   \"figi_exch_cntry\": \"XL\", \n   \"figi_ticker\": \"EWCHF:XL\", \n   \"figi_uniqueid\": \"EQ0000000047899530\", \n   \"last_crsp_adj_date\": null, \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XLON\", \n   \"primary_listing\": false, \n   \"security_name\": \"EDWARDS LIFESCIENCES CORP\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001SF2288\", \n   \"stock_exchange\": \"LSE\", \n   \"ticker\": \"0REN\"\n  }, \n  {\n   \"composite_figi\": \"BBG00C5YWSG9\", \n   \"composite_figi_ticker\": \"EW:SW\", \n   \"currency\": \"CHF\", \n   \"delisted_security\": true, \n   \"etf\": false, \n   \"exch_symbol\": \"^XSWX\", \n   \"figi\": \"BBG00C5YWSJ6\", \n   \"figi_exch_cntry\": \"SE\", \n   \"figi_ticker\": \"EW:SE\", \n   \"figi_uniqueid\": \"EQ0000000047897448\", \n   \"last_crsp_adj_date\": null, \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XSWX\", \n   \"primary_listing\": false, \n   \"security_name\": \"EDWARDS LIFESCIENCES CORP\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001SF2288\", \n   \"stock_exchange\": \"SIX\", \n   \"ticker\": \"EW\"\n  }, \n  {\n   \"composite_figi\": \"BBG000BT0397\", \n   \"composite_figi_ticker\": \"EWL:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": true, \n   \"etf\": false, \n   \"exch_symbol\": \"^XETR\", \n   \"figi\": \"BBG000BT0397\", \n   \"figi_exch_cntry\": \"GR\", \n   \"figi_ticker\": \"EWL:GR\", \n   \"figi_uniqueid\": \"EQ0141500000001001\", \n   \"last_crsp_adj_date\": null, \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XETR\", \n   \"primary_listing\": false, \n   \"security_name\": \"EDWARDS LIFESCIENCES CORP\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001SF2288\", \n   \"stock_exchange\": \"XETRA\", \n   \"ticker\": \"EWL\"\n  }, \n  {\n   \"composite_figi\": \"BBG000BT0397\", \n   \"composite_figi_ticker\": \"EWL:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XSTU\", \n   \"figi\": \"BBG000BT04X8\", \n   \"figi_exch_cntry\": \"GS\", \n   \"figi_ticker\": \"EWL:GS\", \n   \"figi_uniqueid\": \"EQ0141500000001001\", \n   \"last_crsp_adj_date\": null, \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XSTU\", \n   \"primary_listing\": false, \n   \"security_name\": \"EDWARDS LIFESCIENCES CORP\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001SF2288\", \n   \"stock_exchange\": \"STU\", \n   \"ticker\": \"EWL\"\n  }\n ], \n \"short_description\": \"Edwards Lifesciences Corp. engages in the design, development, manufacture, and markets products to treat stage cardiovascular disease. It operates through the following geographical segments: United States, Europe, Japan, and Rest of the World. Its products are categorized into three areas: Surgical Heart Valve Therapy, Transcatheter Heart Valves, and Critical Care. The Surgical Heart Valve Therapy portfolio includes tissue heart valves and heart valve repair products for the surgical replacement or repair of a patient's heart valve. The portfolio also includes a diverse line of cardiac surgery systems used during minimally invasive surgical procedures, and cannulae, embolic protection devices and other products used during cardiopulmonary bypass. The Transcatheter Heart Valves portfolio includes technologies designed to treat heart valve disease using catheter-based approaches as opposed to open surgical techniques. The Critical Care portfolio products include pulmonary artery catheters, disposable pressure transducers and advanced monitoring systems. The portfolio also includes a line of balloon catheter-based vascular products, surgical clips and inserts. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.\", \n \"sic\": 3842, \n \"standardized_active\": true, \n \"stock_exchange\": \"NYSE\", \n \"template\": \"industrial\", \n \"ticker\": \"EW\"\n}"